======================================================================
PANCREATIC DUCTAL ADENOCARCINOMA
FALSE ATTRACTOR ANALYSIS — SCRIPT 1
Dataset: GSE183795
Framework: OrganismCore Principles-First
Doc: 87a | Date: 2026-03-01
======================================================================

  GEO accession : GSE183795
  Tumor samples : 139 PAAD
  Normal samples: 105 adjacent non-tumor
  Platform      : Affymetrix HuGene-1.0-ST
  Survival data : YES
  Stage data    : YES

  PREDICTIONS LOCKED BEFORE DATA:
  Switch: PTF1A/NR5A2/RBPJL/BHLHA15/CPA1/PRSS1 suppressed
  FA:     KRT19/SOX9/MUC1/EPCAM elevated
  EZH2:   ELEVATED (gain lock)
  MYC:    ELEVATED (KRAS driven)
  Survival: depth r < 0 with OS
  Subtype: GATA6 stratifies depth


=== STEP 0: DATA ACQUISITION ===
=================================================================
STEP 0: DATA ACQUISITION
Dataset: GSE183795
  139 PAAD tumors
  105 adjacent non-tumor pancreas
  Affymetrix HuGene-1.0-ST
=================================================================

  Checking for existing downloads...
  Downloading: GSE183795_normalized_matrix.txt.gz
  URL: https://ftp.ncbi.nlm.nih.gov/geo/series/GSE183nnn/GSE183795/suppl/GSE183795_normalized_matrix.txt.gz
  Complete: ./paad_false_attractor/GSE183795_normalized_matrix.txt.gz (19.6 MB)

  File status:
    matrix    : GSE183795_normalized_matrix.txt.gz (19.6 MB)

=== STEP 1: METADATA ===

--- Fetching sample metadata ---
  Fetching from GEO...
  Fetched 244 samples — cached

=== STEP 2: LOAD MATRIX ===

  Loading: GSE183795_normalized_matrix.txt.gz
  Raw shape: 23306 genes x 247 columns
  First 5 columns: ['Transcript ID', 'gene_assignment', 'RefSeq', '10_E33-Tn13_N.CEL', '12_E41-Tn13_N.CEL']
  First 5 index:   ['A1BG', 'A1CF', 'A2M', 'A2ML1', 'A3GALT2']
  Dropping non-numeric columns: ['gene_assignment', 'RefSeq']
  After cleanup: 23306 genes x 245 samples
  Target genes found  : 56/58
  Missing: ['VIMENTIN', 'CTRB1']
  Final shape: (245, 56)
  Index sample: ['Transcript ID', '10_E33-Tn13_N', '12_E41-Tn13_N']

=== STEP 3: MERGE AND CLASSIFY ===

  Merging expression with metadata...
  Merged shape: (245, 62)

  Group counts:
    TUMOR  : 241
    NORMAL : 3
    UNKNOWN: 1

  Stage distribution (tumor):
    IIB: 112
    III: 32
    IIA: 29
    IB: 10
    IV: 7
    IVA: 4
    IVB: 2
    >IIB: 2
    ?: 1
    IA: 1

  Survival (tumor samples):
    n with data: 191
    Median: 12.9 months
    Range: 0.4 – 70.8 months

=== STEP 4: SADDLE POINT ANALYSIS ===

======================================================================
STEP 4: SADDLE POINT ANALYSIS
PAAD TUMOR vs ADJACENT NORMAL PANCREAS
======================================================================
  TUMOR  : 241
  NORMAL : 3

  FRAMEWORK PREDICTIONS (locked before data):
  Switch genes: PTF1A/NR5A2/RBPJL/BHLHA15/CPA1/PRSS1 suppressed
  FA markers:   KRT19/SOX9/MUC1/EPCAM elevated
  Epigenetic:   EZH2 elevated (gain lock)
  Scaffold:     MYC elevated (KRAS driven)

  Gene       Role          Normal     Tumor    Change          p-value  Result
  --------------------------------------------------------------------------------
  PTF1A      SWITCH        7.2056    6.7105     -6.9%      p=0.0412   *  WEAKLY SUPPRESSED
  NR5A2      SWITCH        9.1521    8.0988    -11.5%      p=0.1870  ns  NOT CONFIRMED
  RBPJL      SWITCH        8.6874    7.2836    -16.2%      p=0.0964  ns  NOT CONFIRMED
  BHLHA15    SWITCH        9.0966    7.4966    -17.6%    p=8.61e-03  **  WEAKLY SUPPRESSED
  CPA1       SWITCH       12.4246   10.4667    -15.8%      p=0.1423  ns  NOT CONFIRMED
  PRSS1      SWITCH       12.0554   10.4695    -13.2%      p=0.1983  ns  NOT CONFIRMED
  KRT19      FA            6.5930    8.3962    +27.3%      p=0.0283   *  FA CONFIRMED
  SOX9       FA            7.1323    7.2900     +2.2%      p=0.1229  ns  NOT ELEVATED
  MUC1       FA            8.9634    9.2674     +3.4%      p=0.4444  ns  NOT ELEVATED
  EPCAM      FA            8.3272    9.1227     +9.6%      p=0.0536  ns  NOT ELEVATED
  EZH2       EPIGEN        5.5160    6.0716    +10.1%      p=0.0121   *  SEE DATA
  EED        EPIGEN        7.2429    7.5327     +4.0%      p=0.1068  ns  SEE DATA
  SUZ12      EPIGEN        7.8455    8.0440     +2.5%      p=0.2316  ns  SEE DATA
  TET2       EPIGEN        6.9202    7.3538     +6.3%    p=6.77e-03  **  SEE DATA
  DNMT3A     EPIGEN        6.6779    6.5057     -2.6%      p=0.0766  ns  SEE DATA
  ASXL1      EPIGEN        7.6008    7.3952     -2.7%      p=0.1982  ns  SEE DATA
  KDM6A      EPIGEN        7.3067    7.2290     -1.1%      p=0.4784  ns  SEE DATA
  MYC        SCAFFOLD      8.3467    8.1312     -2.6%      p=0.3142  ns  SEE DATA
  KRAS       SCAFFOLD      7.2076    7.4645     +3.6%      p=0.2005  ns  SEE DATA
  MKI67      SCAFFOLD      5.1936    5.6997     +9.7%      p=0.2316  ns  SEE DATA
  CCND1      SCAFFOLD      8.0702    8.5503     +5.9%      p=0.0706  ns  SEE DATA
  GATA6      SUBTYPE       8.1871    7.8270     -4.4%      p=0.0437   *  SEE DATA
  KRT5       SUBTYPE       5.1493    5.6193     +9.1%      p=0.3370  ns  SEE DATA
  KRT14      SUBTYPE       6.3342    6.3849     +0.8%      p=0.3198  ns  SEE DATA
  VIM        SUBTYPE       9.8365   10.2130     +3.8%      p=0.0939  ns  SEE DATA
  CDH1       SUBTYPE       9.1244    8.9871     -1.5%      p=0.3840  ns  SEE DATA
  CDH2       SUBTYPE       5.1139    5.7163    +11.8%      p=0.0694  ns  SEE DATA
  SNAI1      SUBTYPE       5.2551    5.3735     +2.3%      p=0.4050  ns  SEE DATA
  ZEB1       SUBTYPE       7.2579    7.7935     +7.4%      p=0.0576  ns  SEE DATA
  AMY2A      ACINAR       11.7877   10.1297    -14.1%      p=0.1179  ns  SEE DATA
  AMY2B      ACINAR        7.9718    7.5171     -5.7%      p=0.2243  ns  SEE DATA
  CELA3A     ACINAR       12.5718   10.3940    -17.3%      p=0.1179  ns  SEE DATA
  CELA3B     ACINAR       12.1293   10.1012    -16.7%      p=0.1083  ns  SEE DATA
  CTRB2      ACINAR       12.2850   10.6300    -13.5%      p=0.2512  ns  SEE DATA
  CTRC       ACINAR       11.1942    8.9766    -19.8%      p=0.1460  ns  SEE DATA
  PRSS2      ACINAR       12.1611   10.8015    -11.2%      p=0.1892  ns  SEE DATA
  PRSS3      ACINAR        9.8149    8.2381    -16.1%      p=0.0672  ns  SEE DATA
  PNLIP      ACINAR       11.1973    9.3525    -16.5%      p=0.2146  ns  SEE DATA
  PNLIPRP1   ACINAR       10.9320    8.3401    -23.7%      p=0.1068  ns  SEE DATA
  PNLIPRP2   ACINAR       10.8889    8.6818    -20.3%      p=0.1537  ns  SEE DATA
  CEL        ACINAR       11.6521    9.3016    -20.2%      p=0.1368  ns  SEE DATA
  CPA2       ACINAR       11.9978    9.6395    -19.7%      p=0.1422  ns  SEE DATA
  CPB1       ACINAR       11.9383   10.2373    -14.2%      p=0.1915  ns  SEE DATA
  KRT7       DUCTAL        7.3370    8.1388    +10.9%      p=0.1556  ns  SEE DATA
  KRT18      DUCTAL        9.9193    9.7579     -1.6%      p=0.4057  ns  SEE DATA
  HNF1B      DUCTAL        7.0977    7.0293     -1.0%      p=0.4907  ns  SEE DATA
  CFTR       DUCTAL        8.4628    8.1803     -3.3%      p=0.3810  ns  SEE DATA
  MUC5B      DUCTAL        6.4826    6.8648     +5.9%      p=0.2703  ns  SEE DATA
  MUC6       DUCTAL        8.6712    8.1541     -6.0%      p=0.3284  ns  SEE DATA
  TFF1       DUCTAL        6.4974    7.8015    +20.1%      p=0.0936  ns  SEE DATA
  TFF2       DUCTAL        6.0535    6.7944    +12.2%      p=0.2005  ns  SEE DATA
  SPARC      PROG         10.0967   11.2764    +11.7%      p=0.0187   *  SEE DATA
  POSTN      PROG          5.9158    8.8129    +49.0%    p=9.49e-03  **  SEE DATA
  FN1        PROG          9.4742   10.7682    +13.7%      p=0.0536  ns  SEE DATA
  ACTA2      PROG         10.4523   10.5502     +0.9%      p=0.4141  ns  SEE DATA
  PDGFRA     PROG          8.2041    8.3314     +1.6%      p=0.3457  ns  SEE DATA

  Saved: ./paad_false_attractor/results/saddle_results.csv

=== STEP 5: DEPTH SCORING ===

======================================================================
STEP 5: BLOCK DEPTH SCORING
Score = switch suppression + FA elevation
======================================================================
  Component 1: Switch suppression genes=['PTF1A', 'NR5A2', 'RBPJL', 'BHLHA15', 'CPA1', 'PRSS1']
  Component 2: FA elevation genes=['KRT19', 'SOX9', 'MUC1', 'EPCAM']

  Depth statistics (241 tumors):
    Mean   : 0.5637
    Median : 0.5380
    Std    : 0.1611
    Min    : 0.2506
    Max    : 0.9214
    Q25    : 0.4306
    Q75    : 0.7110

  Block depth by stage:
       IB (n= 10): 0.6061 ± 0.1582
      IIA (n= 29): 0.5623 ± 0.1628
      IIB (n=112): 0.5968 ± 0.1526
      III (n= 32): 0.6330 ± 0.1694
       IV (n=  7): 0.5626 ± 0.1827

  Depth correlations (all genes):
  Gene                r  p-value
  ------------------------------------
  KRT19         +0.8449  p=7.24e-67
  CTRC          -0.7601  p=1.20e-46
  KRAS          +0.7595  p=1.60e-46
  PNLIPRP1      -0.7563  p=6.25e-46
  AMY2A         -0.7506  p=6.65e-45
  PNLIP         -0.7493  p=1.16e-44
  CEL           -0.7454  p=5.54e-44
  RBPJL         -0.7438  p=1.05e-43
  CELA3B        -0.7435  p=1.17e-43
  MKI67         +0.7423  p=1.89e-43
  NR5A2         -0.7420  p=2.17e-43
  CELA3A        -0.7394  p=6.12e-43
  PNLIPRP2      -0.7322  p=9.53e-42
  CPA1          -0.7283  p=4.14e-41
  CPA2          -0.7195  p=1.04e-39
  PTF1A         -0.7085  p=4.87e-38
  CTRB2         -0.7048  p=1.66e-37
  CPB1          -0.7008  p=6.49e-37
  PRSS1         -0.6999  p=8.49e-37
  BHLHA15       -0.6830  p=1.84e-34

=== STEP 6: SURVIVAL ANALYSIS ===

======================================================================
STEP 6: SURVIVAL ANALYSIS
Prediction: depth correlates negatively with survival
Higher depth = more dedifferentiated = worse prognosis
======================================================================

  Samples with survival data: 191

  Depth vs survival (Pearson):
    r = -0.1377  p = 5.75e-02
    Prediction: negative r
    Result: NOT CONFIRMED

  Depth vs survival (Spearman):
    rho = -0.0687  p = 3.45e-01

  High depth (n=96): median survival = 11.3 mo
  Low  depth (n=95): median survival = 13.8 mo
  High vs Low depth (high worse): p=0.0824
  Result: NOT CONFIRMED

  Gene vs survival correlations (top 15):
  Gene                r  p-value  Role
  ------------------------------------------------
  KRT7          -0.2829  p=7.34e-05  DUCTAL
  POSTN         -0.2286  p=1.47e-03  
  FN1           -0.2163  p=2.66e-03  
  MKI67         -0.2157  p=2.72e-03  SCAFFOLD
  KRT18         -0.2034  p=4.76e-03  DUCTAL
  KRT19         -0.1976  p=6.15e-03  FA
  AMY2B         +0.1936  p=7.28e-03  ACINAR
  KRAS          -0.1885  p=9.01e-03  SCAFFOLD
  DNMT3A        -0.1832  p=1.12e-02  EPIGEN
  KDM6A         -0.1506  p=3.76e-02  EPIGEN
  EZH2          -0.1504  p=3.78e-02  EPIGEN
  KRT5          -0.1504  p=3.79e-02  
  MYC           +0.1488  p=3.99e-02  SCAFFOLD
  CDH2          -0.1443  p=4.64e-02  
  MUC6          +0.1409  p=5.18e-02  DUCTAL

=== STEP 7: SUBTYPE ANALYSIS ===

======================================================================
STEP 7: SUBTYPE ANALYSIS
Prediction: GATA6 stratifies depth
Classical (GATA6 high) = shallower
Basal-like (GATA6 low) = deeper
======================================================================

  GATA6 median: 7.8567
  Classical (GATA6 high): n=121
  Basal-like (GATA6 low): n=120

  Classical depth: 0.5100 ± 0.1483
  Basal depth:     0.6178 ± 0.1559

  Basal > Classical: p=0.0000
  Prediction: Basal deeper
  Result: CONFIRMED

  Classical survival: 13.8 mo
  Basal survival:     12.6 mo
  Classical > Basal: p=0.1722

  Gene           Classical       Basal    Change
  ------------------------------------------------
  PTF1A             6.9841      6.4346     -7.9%
  NR5A2             8.9958      7.1944    -20.0%
  RBPJL             8.2960      6.2628    -24.5%
  BHLHA15           8.0334      6.9554    -13.4%
  KRT19             7.9402      8.8560    +11.5%
  SOX9              7.4512      7.1274     -4.3%
  MUC1              9.4983      9.0346     -4.9%
  GATA6             8.1330      7.5184     -7.6%
  EZH2              5.9575      6.1867     +3.8%
  MYC               8.3632      7.8974     -5.6%

=== STEP 8: DRUG TARGET DERIVATION ===

======================================================================
STEP 8: DRUG TARGET DERIVATION
From geometry — before literature
======================================================================

  Switch gene expression:
  Gene            Normal     Tumor    Change
  --------------------------------------------
  PTF1A           7.2056    6.7105     -6.9%
  NR5A2           9.1521    8.0988    -11.5%
  RBPJL           8.6874    7.2836    -16.2%
  BHLHA15         9.0966    7.4966    -17.6%
  CPA1           12.4246   10.4667    -15.8%
  PRSS1          12.0554   10.4695    -13.2%

  EZH2 status:
    Normal: 5.5160  Tumor: 6.0716  Change: +10.1%
    Prediction: ELEVATED
    Result: CONFIRMED

  ============================================================
  DRUG TARGET PREDICTIONS — GEOMETRY-DERIVED
  Stated before literature consultation
  ============================================================

  PREDICTION 1: EZH2 INHIBITOR
    Geometry: EZH2 gain-of-function lock
              Silences acinar TF program
              PTF1A locus H3K27me3 methylated
    Drug:     Tazemetostat (FDA approved)
              EZH2 inhibitor + gemcitabine
    Mechanism: Demethylate acinar gene loci
               Restore PTF1A/NR5A2 expression
               Dissolve false attractor

  PREDICTION 2: PTF1A RESTORATION / HMA
    Geometry: PTF1A is the master switch gene
              Its suppression is the block
    Drug:     Azacitidine/decitabine
              Demethylate PTF1A promoter
              Or: direct CRISPRa at PTF1A locus
    Mechanism: Restore acinar identity
               → PAAD cannot maintain
               ductal/mesenchymal phenotype

  PREDICTION 3: BET INHIBITOR / MYC AXIS
    Geometry: MYC elevated (KRAS driven)
              MYC maintains dedifferentiation
    Drug:     JQ1 / BET inhibitor
              OMO-103 (MYC inhibitor in trials)
    Mechanism: Reduce MYC transcription
               Collapse proliferative drive
               at the block point
               Combined with differentiation
               therapy (EZH2i) for dual attack

  PREDICTION 4: DEPTH SCORE AS BIOMARKER
    Geometry: Block depth correlates with survival
              High depth = basal-like = worse OS
    Clinical: Depth score at diagnosis stratifies
              high-risk vs low-risk PAAD
              High depth → aggressive combo therapy
              Low depth → single agent tolerable
  ============================================================
    

=== STEP 9: FIGURE ===

  Figure saved: ./paad_false_attractor/results/paad_false_attractor.png